Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control

DOI10.1155/2012/567819MaRDI QIDQ454783zbMATH OpenOpenAlexWikidataFDO

Authors Mourad Tighiouart, Galen Cook-Wiens, André Rogatko

Publication date 10 October 2012

Published in Journal of Probability and Statistics (Search for Journal in Brave)

Copyright license Creative Commons Attribution 4.0 International

Full work available at URL https://doi.org/10.1155/2012/567819

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
• Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
• Dose-finding with two agents in phase I oncology trials
• Designs foe phase i cancer clinical trials with differentiation of graded toxicity
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION

Cites work

• scientific article; zbMATH DE number 524373 (Why is no real title available?)
• A Curve‐Free Method for Phase I Clinical Trials
• Bayesian Nonparametric Inference on the Dose Level with Specified Response Rate
• Bayesian optimal designs for phase I clinical trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Continual reassessment method for ordered groups
• Dose finding in drug development.
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Statistical Methods for Dose‐Finding Experiments
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

Cited in

(8)

• Patient-specific dose finding in phase I clinical trials
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Number of patients per cohort and sample size considerations using dose escalation with overdose control
• Adaptive clinical trial designs for phase I cancer studies
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Adjusting Simon'S optimal two-stage design for heterogeneous populations based on stratification or using historical controls
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate

This page was built for publication: Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q454783)